Bayer Plans Finerenone Phase 2 Study in Combination with Empagliflozin

(PLX AI) - Bayer extends clinical development program for finerenone with Phase II study investigating the initial combination therapy with empagliflozin in patients with chronic kidney disease and type

Related Keywords

,Bayer ,Plans ,Finerenone ,Hase ,Study ,Combination ,Empagliflozin ,